Pharma Daily — September 9, 2026

17 material deal events, 0 FDA approvals, and 12 Phase 2/3 primary completions queued for the next 90 days. The window’s two largest items sit at opposite ends of the risk spectrum: a $12B acquisition centerpiece failed Phase 3, while a $2.1B license landed with no disclosed upfront.

TL;DR — The Sep 8–9 window produced 17 material deal events after one $10B extraction-artifact row was removed; headline totals include $12B for Novartis’s Avidity acquisition and $2.1B for Monte Rosa’s license to Novartis. Zero FDA approvals landed, with 12 Phase 2/3 readouts due within 90 days (top 8 shown below). Comp base is thin — only 5 historical deals — so percentiles are directional.

Deals

Table 1: Deal events in the collection window (Sep 8–9, 2026), sorted by disclosed total. “undisclosed” means the source gives no number — we never estimate.

Comp context: our accumulated comp base holds only 5 historical deals with disclosed totals (median $1.0B), so percentiles this week are directional at best. Structure note: every disclosed total in the table lacks a disclosed upfront, and milestone-heavy headline totals overstate near-term cash. Data caveat: one collected row tagged $10B (cardiology, cell therapy) was excluded because the cited BioPharma Dive article contains no matching transaction.

Figure 1: Largest disclosed total $12B — vs 5 accumulated comps (thin base; treat as ranking, not valuation evidence).

Approvals

openFDA’s Drugs@FDA feed recorded no approvals in this window — consistent with the absence-as-signal pattern that quiet weekdays often cluster before PDUFA batches.

Readout Calendar

Table 2: Highest-ranked Phase 2/3 primary completions due in the next 90 days (score = phase weight × log enrollment × sponsor factor).

Market Reaction

GLUE (Monte Rosa Therapeutics) — +1.4% on the day (as of 2026-09-09). The muted move fits a back-loaded license structure with no disclosed upfront.

One Take

The most useful signal in this window is absence: zero FDA approvals on a weekday, and the window’s data shows the absence-as-signal pattern — quiet weekdays tend to cluster before PDUFA batches, so the next five sessions are the ones to watch. Against that quiet backdrop, the $12B Novartis–Avidity Biosciences acquisition is the dominant event; it sits at the 100th percentile of our thin 5-deal comp base, yet the lead asset del-desiran just missed its Phase 3 primary endpoint in myotonic dystrophy type 1, putting the deal’s strategic rationale under pressure. Monte Rosa’s $2.1B license to Novartis ranks second by headline, but no upfront was disclosed and GLUE moved only +1.4% — the market is treating the headline as distant optionality, not cash. My read: this is a window of repricing risk rather than momentum; the absence of approvals and the Avidity Phase 3 miss together suggest near-term catalysts will be sparse and skewed negative until the next PDUFA batch. Conviction: moderate. What would change my mind: an unexpected FDA approval in the next 2–3 sessions, or Novartis disclosing a salvage path for del-desiran.

Key takeaways

• Zero FDA approvals in the Sep 8–9 window; the absence-as-signal pattern puts the watch on the next 5 sessions.
• Novartis’s $12B Avidity acquisition is at the 100th percentile of only 5 comps, and its lead asset failed Phase 3 — a structure-vs-outcome mismatch.
• Monte Rosa’s $2.1B license to Novartis ranks at the 80th percentile but carried no disclosed upfront; the stock rose just 1.4%.
• Keros Therapeutics’ $20M license sits at the 20th percentile of the same thin comp base.
• One $10B collected row was a data-extraction artifact and was excluded from the narrative after the cited source was checked.

FAQ

Why did Monte Rosa’s stock rise only 1.4% on a $2.1B headline?

The 8-K discloses no upfront and up to $2.1B in milestones tied to Phase 2 starts, regulatory events, and sales — a back-loaded structure the market reads as contingent value.

What happened to Novartis’s $12B Avidity acquisition?

The Phase 3 Harbor trial of del-desiran in myotonic dystrophy type 1 missed its primary endpoint of video hand opening time; Novartis said it will analyze the full dataset and discuss next steps with regulators.

How reliable are the deal percentiles?

They are based on only 5 historical comps with disclosed totals — directional rankings, not valuation evidence.

Sources

• Monte Rosa Therapeutics, Inc. 8-K mentioning license agreement — SEC EDGAR
• Adicet Bio, Inc. 8-K mentioning license agreement — SEC EDGAR
• BrainChild Bio gets $116M for pivotal trial of pediatric brain tumor CAR-T — Endpoints News
• Moonwalk raises $70M to test siRNA treatment for obesity — Endpoints News
• Cancer biotech TwoStep gets $62.5M to take twist on ADCs into clinic — Endpoints News
• Roivant surges on ‘exceptional’ results; Bristol Myers touts first-of-its-kind CAR-T therapy — BioPharma Dive
• Solstice rises with $225M series A to advance next-gen CTLA-4 immunotherapy into phase 2 — FierceBiotech
• Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test — FierceBiotech
• Kura Oncology spins out diabetes pipeline with $50M and Lilly’s help — Endpoints News
• Keros Therapeutics, Inc. 8-K mentioning license agreement — SEC EDGAR
• Luma locks down 15-year, $410M fund for life science investments — FierceBiotech
• Sandoz sets sights on 100 biosimilars in new 2040 strategy, with $300M facility build — FiercePharma
• GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing — FierceBiotech
• Schrödinger births new immunology and inflammation biotech, Tectora Therapeutics — FierceBiotech
• ARPA-H Selects UpDoc to Lead Development of Autonomous Clinical AI System, in an Initiative Joined by Microsoft, OpenAI and NVIDIA — PR Newswire
• Partillion Bioscience secures $2.1M NIH SBIR grant — PR Newswire
• Kura Oncology, Inc. 8-K mentioning license agreement — SEC EDGAR
• Expanding its biopharma plans, Anthropic looks for a life sciences dealmaker — Endpoints News
• Belzutifan + pembrolizumab Phase 3 (NCT05239728) — ClinicalTrials.gov
• Encorafenib + binimetinib + pembrolizumab Phase 3 (NCT04657991) — ClinicalTrials.gov
• Ritlecitinib Phase 3 (NCT07029711) — ClinicalTrials.gov
• Povidone-iodine surgical site infection Phase 3 (NCT06363877) — ClinicalTrials.gov
• IMU-838 multiple sclerosis Phase 3 (NCT05201638) — ClinicalTrials.gov
• Tranexamic acid abdominal surgery Phase 3 (NCT06414031) — ClinicalTrials.gov
• Short RT vs RCT rectal cancer Phase 3 (NCT04246684) — ClinicalTrials.gov
• Opioid-sparing gender-affirming surgery Phase 3 (NCT04979338) — ClinicalTrials.gov

All items above are drawn from first-hand public sources — SEC filings, trial registries, and company releases — collected 2026-09-09. No sources failed in this window. One collected row ($10B cardiology/cell therapy) was excluded after the cited BioPharma Dive article was found to contain no matching transaction. Related: Pharma Daily — September 4, 2026.